Navigation Links
Serina Therapeutics Awarded Patent for Its Core Polymer Drug Delivery Technology
Date:5/20/2011

HUNTSVILLE, Ala., May 20, 2011 /PRNewswire/ -- Serina Therapeutics, Inc., a pharmaceutical research and development company, announced that the company was awarded a patent from the United States Patent and Trademark Office covering its polymer technology.  The patent entitled "Polyoxazoline and compositions comprising the same" (U.S. Patent No. 7,943,141) covers the synthesis and composition of polyoxazolines for the delivery of different drug molecules.      

The patent represents years of groundbreaking research in the development of safe polyoxazoline polymers for drug delivery.  It is the first of many patents that Serina has applied for.  "This patent award validates our invention and design of a novel drug delivery platform and allows Serina the opportunity to advance some of its proprietary ideas towards full development and eventually commercialization," said Dr. Michael D. Bentley, Chief Scientific Officer and cofounder of the company. "We are now in a position to build a strong pipeline of polymer therapeutic molecules."  

About Serina

Serina Therapeutics is a privately held pharmaceutical company that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms.  The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled nine approved polyethylene glycol (PEG) products for various pharmaceutical partners.  Besides developing its own pipeline of pharmaceutical products, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.  

For more information on Serina Therapeutics, please visit http://www.serinatherapeutics.com

Media Contact:  Karen Petersen, 256-327-9434


'/>"/>
SOURCE Serina Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Pearl Therapeutics Phase 2b Results Show a 50% Improvement in Lung Function with PT003 Compared to Spiriva® and Foradil® in Patients with COPD
2. Translational Science Expert, Dr. Melissa Ashlock, Joins aTyr Pharma to Advance Physiocrine-based Therapeutics
3. Regency Therapeutics and Daiichi Sankyo Announce Launch and Commercial Availability of SPRIX® (ketorolac tromethamine) Nasal Spray
4. Inhibikase Therapeutics Elects Steven C. Gilman, Ph.D., to Board of Directors
5. Echo Therapeutics Appoints Christopher P. Schnittker as Chief Financial Officer
6. Healthpoint Biotherapeutics Introduces OASIS® Ultra Tri-Layer Matrix
7. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
8. Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results
9. Cell Therapeutics Announces Planned Reverse Stock Split; Receives NASDAQ Notice of Non-Compliance; Intends to Request Hearing
10. Echo Therapeutics Expands Into New Headquarters in Philadelphia
11. Pearl Therapeutics Highlights Its Porous Particle Cosuspension Platform, Demonstrating Universal Applicability Across Multiple Drug Classes and Combination Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Research and Markets has announced the addition of ... report to their offering. ... This research service on the global pharmaceutical stability ... a snapshot of the key participants in the market. ... 2016 to 2020. The market is expected to grow at a ...
(Date:1/19/2017)... , Jan. 19, 2017 ... Summary GlobalData,s new report, "Germany Cataract Surgery ... on the Germany Cataract Surgery Devices market. The report ... units) and average prices (USD) within market segements - ... report also provides company shares and distribution shares data ...
(Date:1/19/2017)... Conference Call and Webcast to Follow Vanda Pharmaceuticals Inc. ... results for the fourth quarter of 2016 on Wednesday, February 15, ... ... PM ET on Wednesday, February 15, 2017, during which management will ... other corporate activities. To participate in the conference call, please dial ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... January 20, 2017 , ... Doctor C LLC, a company based out ... trade show to continue the marketing and distribution of its product, The Right C. ... 400 percent better absorption than traditional vitamin C supplements. At the trade show, Doctor ...
(Date:1/20/2017)... ... , ... Michael and Betsy Brauser celebrated 5 years of Betsy’s participation in ... has been life-saving as she has been on the trial for more than ... with ovarian cancer in 2009. She underwent standard chemotherapy but a year later went ...
(Date:1/20/2017)... ... ... “Code Word: Chocolate Biscuit”: a biographical account following a man who went on to support ... author, Marlyn Ivey, born in Lynn Haven, Florida and at the age of 5, his ... of age, he joined the Navy and got married right out of boot camp. ...
(Date:1/20/2017)... ... ... “Knowledge is God’s Lighthouse”: a moving and colorful collection of prayers that reminds ... published author, Gene Gaapf, a retired truck driver, and a long-time writer, whose published ... high school and have many different titles,” Gaapf mentions about his different works. “I ...
(Date:1/19/2017)... ... 2017 , ... Next week after January 20th, the fear for many is ... circumvent health needs of over 30 million. Many interviews with Dr. Carol Francis at ... public servants were suppose to prioritize. Interviews provided below. , Among those ...
Breaking Medicine News(10 mins):